Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes

Guoyue Yuan; Jue Jia; Caili Zhang; Shuqin Yu; Sijing Dong; Jingjing Ye; Tianyi Zhu; Bingqian Tang; Weiyun Qian; Dong Wang; Ling Yang; Libin Zhou; Chaoming Mao

doi:10.1507/endocrj.EJ13-0483

ORIGINALS

Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes

Guoyue Yuan, Jue Jia, Caili Zhang, Shuqin Yu, Sijing Dong, Jingjing Ye, Tianyi Zhu, Bingqian Tang, Weiyun Qian, Dong Wang, Ling Yang, Libin Zhou, Chaoming Mao

Author information

Guoyue Yuan
Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China
Jue Jia
Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China
Caili Zhang
Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China
Shuqin Yu
Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China
Sijing Dong
Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China
Jingjing Ye
Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China
Tianyi Zhu
Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China
Bingqian Tang
Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China
Weiyun Qian
Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China
Dong Wang
Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China
Ling Yang
Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China
Libin Zhou
Ruijin Hospital, Center of Molecular Medicine, Shanghai Institute of Endocrine And Metabolic Diseases, State Key Laboratory of Medical Genomics, Shanghai Jiaotong University Medical School, Shanghai 200025, China
Chaoming Mao
Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China

Keywords: Sitagliptin, Continuous subcutaneous insulin infusion (CSII), Newly diagnosed, Type 2 diabetes, Dipeptidyl peptidase-4(DPP-4)

JOURNAL FREE ACCESS

2014 Volume 61 Issue 5 Pages 513-521

DOI https://doi.org/10.1507/endocrj.EJ13-0483

Browse “Advance online publication” version

Details

Abstract

Sitagliptin was used as monotherapy or in combination with metformin, thiazolidinedione or sulfonylurea. It is not clear whether effects are enhanced or unique when in combination with transient continuous subcutaneous insulin infusion (CSII) therapy. The aim of this study was to assess the safety and efficacy of sitagliptin in combination with transient CSII therapy in patients with newly diagnosed type 2 diabetes. Eighty patients with newly diagnosed type 2 diabetes from July 2011 to May 2013 were recruited into the study. These patients were randomly divided into a CSII monotherapy group (group A, n = 40) or a sitagliptin in combination with CSII therapy group (group B, n = 40) and received insulin intensive therapy. Treatments were maintained for 2 weeks. 75g oral glucose tolerance test (OGTT) was performed before and after treatments, and the levels of glucose, insulin and C-peptide were examined. The results indicated that, compared with CSII therapy group, the level of plasma glucose significantly decreased, the levels of insulin and C-peptide strikingly increased and homeostasis model assessment for beta-cell function (HOMA-β) and Insulinogenic index (Ins index) were improved in the group of sitagliptin in combination with CSII therapy. Above all, the incidence of hypoglycemia was lower, insulin doses were less and the rate of recovery to normal glucose tolerance (NGT) or impaired glucose tolerance (IGT) determined by 75gOGTT was higher in the latter. So, Sitagliptin in combination with CSII therapy can be a new safe and effective therapy in patients with newly diagnosed type 2diabetes.

Corresponding author

Register with J-STAGE for free!